NINGBO MENOVO PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.77 CNY | +0.47% |
|
+5.02% | -33.21% |
| 23/04 | Menovo Pharmaceutical Unit Gets Approval to Register Vildagliptin Tablets | MT |
| 16/04 | Ningbo Menovo Pharmaceutical Co., Ltd. cancelled the transaction announced on July 20, 2023 | CI |
| Sales 2023 * | 1.5B 206M 17.2B | Sales 2024 * | 1.75B 241M 20.08B | Capitalization | 2.72B 376M 31.34B |
|---|---|---|---|---|---|
| Net income 2023 * | 120M 16.56M 1.38B | Net income 2024 * | 229M 31.61M 2.63B | EV / Sales 2023 * | 1.82 x |
| Net cash position 2023 * | - 0 0 | Net cash position 2024 * | - 0 0 | EV / Sales 2024 * | 1.56 x |
| P/E ratio 2023 * |
22.8
x | P/E ratio 2024 * |
11.9
x | Employees | 2,297 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 68.38% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.47% | ||
| 1 week | +5.02% | ||
| Current month | -8.92% | ||
| 1 month | -8.98% | ||
| 3 months | -17.13% | ||
| 6 months | -35.70% | ||
| Current year | -33.21% |
1 week
12.21
12.89
1 month
11.9114.35
Current year
9.9619.51
1 year
9.9622.02
3 years
9.9662.05
5 years
9.9662.05
10 years
9.6662.05
| Managers | Title | Age | Since |
|---|---|---|---|
Cheng Zhi Yao
CEO | Chief Executive Officer | 49 | 19/04/19 |
Gao Feng Ying
DFI | Director of Finance/CFO | 53 | 12/19/12 |
Xiao Qing Zhang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Zhi Yao
CEO | Chief Executive Officer | 49 | 19/04/19 |
Zhi Yan Fan
PRN | Corporate Officer/Principal | 41 | - |
Qian Cao
BRD | Director/Board Member | 42 | 20/18/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 12.77 | +0.47% | 2,185,822 |
| 25/24/25 | 12.71 | +1.68% | 2,242,291 |
| 24/24/24 | 12.5 | +0.81% | 1,554,804 |
| 23/24/23 | 12.4 | +0.16% | 2,157,040 |
| 22/24/22 | 12.38 | +1.81% | 2,351,171 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Ningbo Menovo Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research, development, manufacture and sales of special active pharmaceutical ingredients (APIs) and medical intermediates. The Companyâs products contain gastropathic medicine and cardiovascular medicine, which include anti-hypertension medicine, anti-hyperlipidemia medicine and anti-thrombus medicine. The Company distributes its products to both domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
30/04/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.77
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -33.21% | 376M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 603538 Stock
